

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and CEO
(Code no.: 4568, First Section, Tokyo, Osaka, and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Daiichi Sankyo Establishes New Department for Vaccine Business

TOKYO, Japan (July 31, 2009) – Daiichi Sankyo Company, Limited announced today the launch of “Vaccine Business Planning Department” as of October 1, 2009, to further enhance its vaccine business.

Medical needs for vaccines have been increasing more than ever, following the increased risk of emerging infectious diseases including the H1N1 pandemic virus, and the strained healthcare expenditures worldwide. At the same time, the numbers of Vaccine Preventable Diseases are on the rise, thanks to the creation of breakthrough vaccines generated through advanced technologies.

Daiichi Sankyo has been focusing on vaccine business throughout its long history. With the establishment of this new organization dedicated to vaccine business, Daiichi Sankyo will further strive to offer excellent medical treatments, not only to cure diseases, but also to prevent them.

###